Next Article in Journal
Physicochemical Properties of a New PEGylated Polybenzofulvene Brush for Drug Encapsulation
Next Article in Special Issue
Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute
Previous Article in Journal
Molecular Interactions for the Curcumin-Polymer Complex with Enhanced Anti-Inflammatory Effects
Previous Article in Special Issue
Therapeutic Applications of Pretargeting
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 11
Issue 9
10.3390/pharmaceutics11090443
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy

by
Agnieszka Majkowska-Pilip
*,
Paweł Krzysztof Halik
and
Ewa Gniazdowska
Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(9), 443; https://doi.org/10.3390/pharmaceutics11090443
Submission received: 7 June 2019 / Revised: 15 August 2019 / Accepted: 16 August 2019 / Published: 1 September 2019
(This article belongs to the Special Issue Targeted Radionuclide Tumor Therapy)
Browse Figures
Review Reports Versions Notes

Abstract

To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy.
Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging
Graphical Abstract

Share and Cite

MDPI and ACS Style

Majkowska-Pilip, A.; Halik, P.K.; Gniazdowska, E. The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy. Pharmaceutics 2019, 11, 443. https://doi.org/10.3390/pharmaceutics11090443

AMA Style

Majkowska-Pilip A, Halik PK, Gniazdowska E. The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy. Pharmaceutics. 2019; 11(9):443. https://doi.org/10.3390/pharmaceutics11090443

Chicago/Turabian Style

Majkowska-Pilip, Agnieszka, Paweł Krzysztof Halik, and Ewa Gniazdowska. 2019. "The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy" Pharmaceutics 11, no. 9: 443. https://doi.org/10.3390/pharmaceutics11090443

APA Style

Majkowska-Pilip, A., Halik, P. K., & Gniazdowska, E. (2019). The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy. Pharmaceutics, 11(9), 443. https://doi.org/10.3390/pharmaceutics11090443

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop